Shanghai Haixin Group Co., Ltd. (SHSE: 600851)
Health Care · Pharmaceuticals · CN
CN¥8.76
+0.69% today · +20.2% 1Y
Shanghai Haixin Group Co., Ltd. (SHSE: 600851) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.08B and employs 675 people.
Over the last twelve months the share price has gained 20.2%, trading between 6.40 and 10.69.
Tweenvest scores Shanghai Haixin Group Co., Ltd. across four factors: quality 68/100, value 32/100, growth 32/100, dividend 13/100. Its strongest factor is quality.
600851 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.08B
- Revenue (TTM)
- $102.62M
- P/E
- 53.48
- EPS
- 0.16
- Dividend yield
- 0.57%
- Beta (5Y)
- 0.59
- 52-week high
- CN¥10.69
- 52-week low
- CN¥6.40
- Avg volume (3M)
- —
- Shares outstanding
- 1.21B
- Employees
- 675
- Next earnings
- —
About Shanghai Haixin Group Co., Ltd.
Shanghai Haixin Group Co., Ltd., which was founded in Shanghai, China, in 1986, is a diverse company. Its core activities involve the pharmaceutical, textile and apparel, and financial services industries. The group also maintains operations within the industrial park sector.
- ISIN
- CNE000000CF1
- Founded
- 1986
- Listed since
- Apr 4, 1994
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.75 | +0.19% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $153.56 | +0.66% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.90 | -1.25% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.25% |
Figures last refreshed Aug 18, 2026.